Home Tags BAY 94-9343

Tag: BAY 94-9343

Anetumab Ravtansine Demonstrates Encouraging Preliminary Antitumor Activity in Heavily Pretreated Mesothelin-expressing...

In a phase I clinical trial, the investigational antibody-drug conjugate (ADC) anetumab ravtansine (BAY 94-9343; Bayer) shows promising antitumor activity in heavily pretreated patients with...

ASCO 2016 Emphasizes Collective Wisdom: The Future of Patient-Centered Care and...

Only a few weeks until the start of the 2016 annual meeting of the American Society of Clinical Oncology (ASCO). This year’s ASCO, taking...

X